WEBULL
News
SPRC
0.5964
-0.15%
-0.0009
SciSparc Sets Up $10 Million Convertible Note Facility With Warrants
TipRanks · 1d ago
Scisparc Ltd. launches $10 million convertible promissory note offering
Reuters · 1d ago
Weekly Report: what happened at SPRC last week (0202-0206)?
Weekly Report · 5d ago
SciSparc Shareholders Approve February Governance Agenda
TipRanks · 02/04 21:30
Scisparc Ltd. Held Special Shareholder Meeting
Reuters · 02/04 21:02
SciSparc files $50M mixed securities shelf
TipRanks · 02/03 21:40
Scisparc Files Prospectus For Offering $50M Securities
Benzinga · 02/03 21:39
SciSparc Subsidiary NeuroThera Wins U.S. Patent for Cannabinoid-Based Antimicrobial Resistance Platform
TipRanks · 02/02 21:30
SciSparc says Neurothera Labs granted U.S. patent for cannabinoid tech
TipRanks · 02/02 13:36
SciSparc Ltd.: NeuroThera Labs Granted U.S. Patent for Cannabinoid-Enhanced Antimicrobial Technology to Combat Antibiotic Resistance
Reuters · 02/02 13:24
Weekly Report: what happened at SPRC last week (0126-0130)?
Weekly Report · 02/02 10:06
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
Barchart · 02/02 07:24
SciSparc Closes Acquisition of Xylo GERD Device IP, Moves to Immediate Commercialization
TipRanks · 01/26 21:27
SciSparc completes acquisition of IP portfolio of patents, trademarks
TipRanks · 01/26 13:20
CORRECTION: SciSparc Acquires MUSE IP Portfolio From Xylo in Equity-Based Asset Deal; SciSparc Issued To Xylo An Amount Of Ordinary Shares Of The Company, Which Represents 19.99% Of The Issued And Outstanding Share Capital Of SciSparc
Benzinga · 01/26 13:19
SciSparc Acquires IP Portfolio Of Patents, Trademarks, IP Rights For Endoscopic Systems, Medical Cameras; Financial Terms Not Disclosed
Benzinga · 01/26 13:17
SciSparc Closes Acquisition of MUSE Endoscopic System IP from Xylo Technologies
Reuters · 01/26 13:13
SciSparc Acquires MUSE System IP Portfolio from Xylo Technologies
Reuters · 01/26 13:13
SCISPARC SUCCESSFULLY COMPLETES ACQUISITION OF IP PORTFOLIO, ADVANCES TOWARD IMMEDIATE COMMERCIALIZATION
Reuters · 01/26 13:13
Weekly Report: what happened at SPRC last week (0119-0123)?
Weekly Report · 01/26 10:06
More
Webull provides a variety of real-time SPRC stock news. You can receive the latest news about Scisparc through multiple platforms. This information may help you make smarter investment decisions.
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.